Close Menu

NEW YORK – Burning Rock has started a 14,000-patient trial called the Pan-Cancer Early Detection Project (PREDICT) to further validate its cell-free DNA early detection technology.

The oncology-focused, Shanghai-based molecular diagnostics firm is working with the Shanghai Zhongshan Hospital and other medical centers to enroll thousands of patients into PREDICT with the goal of validating its cfDNA test in multiple tumor types. The test, which Burning Rock has been developing for four years, is based on its ELSA-seq technology and gauges methylation profiles.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Jul
14

This webinar will describe a rapid metagenomics assay under development for human pathogens, including the SARS-CoV-2 coronavirus.

Jul
15
Sponsored by
LGC SeraCare Life Sciences

Cancer immunotherapy is an exciting new advance for the successful treatment of many forms of metastatic cancer.

Jul
23

This webinar will discuss a study that set to assess the efficacy and safety of osimertinib in EGFR T790M positive non-small cell lung cancer (NSCLC) patients identified by using plasma sample and cobas EGFR Mutation test v2. This is the first prospective study to use liquid biopsy upfront to evaluate osimertinib efficacy.